Heart Failure Clinical Trials in Seattle, Washington

12 studies are recruiting for heart failure in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

   This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.

   Stage

   Phase 2

   Ages

   0 to 17

   Site

   Seattle Children's Hospital-Cardiology/Fetal Therapy ( Site 0019), Seattle, Washington

   Locations

   109 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05714085 on ClinicalTrials.gov

2. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

   The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…

   Stage

   Not phased

   Ages

   0 to 20

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   52 in total

   Run by

   Duke University

   See if you can join NCT04278404 on ClinicalTrials.gov

3. A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

   This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empa…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Virginia Mason Medical Center, Seattle, Washington

   Locations

   652 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06424288 on ClinicalTrials.gov

4. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

   This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Swedish Medical Center_Seattle, Seattle, Washington

   Locations

   838 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07567001 on ClinicalTrials.gov

5. Alleviant ALLAY-HF Study

   Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.

   Stage

   Not phased

   Ages

   40 and older

   Site

   University of Washington, Seattle, Washington

   Locations

   93 in total

   Run by

   Alleviant Medical, Inc.

   See if you can join NCT05685303 on ClinicalTrials.gov

6. Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

   There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to: 1. To evaluate the safety and effectiveness of the Cardiohelp Device for VA-ECMO (heart-lung support) for up to 30 days of sup…

   Stage

   Phase 2

   Ages

   0 to 16

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   5 in total

   Run by

   Stanford University

   See if you can join NCT06080074 on ClinicalTrials.gov

7. Assessment of CCM in HF With Higher Ejection Fraction

   The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Swedish Medical Center, Seattle, Washington

   Locations

   105 in total

   Run by

   Impulse Dynamics

   See if you can join NCT05064709 on ClinicalTrials.gov

8. Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

   Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because …

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   University of Washington, Seattle, Washington

   Locations

   19 in total

   Run by

   Alessandro Doria

   See if you can join NCT06217302 on ClinicalTrials.gov

9. XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

   The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Washington Medical Center, Seattle, Washington

   Locations

   14 in total

   Run by

   XVIVO Perfusion

   See if you can join NCT06895070 on ClinicalTrials.gov

10. Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

    Heart failure (HF) is a growing health and economic burden around the globe, and it remains a leading cause of morbidity and mortality among the general population. HIV is recognized as an independent risk factor for HF, due to direct and indirect effects. Furthermore, people living with HIV (PLWH)…

    Stage

    Not phased

    Ages

    40 and older

    Site

    University of Washington, Seattle, Washington

    Locations

    2 in total

    Run by

    University of Washington

    See if you can join NCT07105007 on ClinicalTrials.gov

11. Left vs Left Randomized Clinical Trial

    The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications an…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Washington, Seattle, Washington

    Locations

    71 in total

    Run by

    Baylor College of Medicine

    See if you can join NCT05650658 on ClinicalTrials.gov

12. Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

    It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that corre…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    University of Washington Medicine, Seattle, Washington

    Locations

    5 in total

    Run by

    Sardocor Corp.

    See if you can join NCT04703842 on ClinicalTrials.gov